CoChat
Sign Up
Cited by 346

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Heart Failure in Cardiomyopathies: A Position Paper from the Heart Failure Association of the European Society of Cardiology

Seferović, Petar M., Polovina, Marija, Bauersachs, Johann, Arad, Michael, Ben Gal, Tuvia, Lund, Lars H., Felix, Stephan B., Arbustini, Eloisa, Caforio, Alida L.P., Farmakis, Dimitrios, Filippatos, Gerasimos S., Gialafos, Elias, Kanjuh, Vladimir, Krljanac, Gordana, Limongelli, Giuseppe, Linhart, Aleš, Lyon, Alexander R., Maksimović, Ružica, Miličić, Davor, Milinković, Ivan, Noutsias, Michel, Oto, Ali, Oto, Öztekin, Pavlović, Siniša U., Piepoli, Massimo F., Ristić, Arsen D., Rosano, Giuseppe M.C., Seggewiss, Hubert, Ašanin, Milika, Seferović, Jelena P., Ruschitzka, Frank, Čelutkiene, Jelena, Jaarsma, Tiny, Mueller, Christian, Moura, Brenda, Hill, Loreena, Volterrani, Maurizio, Lopatin, Yuri, Metra, Marco, Backs, Johannes, Mullens, Wilfried, Chioncel, Ovidiu, de Boer, Rudolf A., Anker, Stefan, Rapezzi, Claudio, Coats, Andrew J.S., Tschöpe, Carsten·2019·European Journal of Heart Failure
DOI 10.1002/ejhf.1461
Open this paper in CoChat — free account

Abstract

Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. In DCM, HF with reduced ejection fraction (HFrEF) has high incidence and prevalence and represents the most frequent cause of death, despite improvements in treatment. In addition, advanced HF in DCM is one of the leading indications for heart transplantation. In HCM, HF with preserved ejection (HFpEF) affects most patients with obstructive, and ∼10% of patients with non-obstructive HCM. A timely treatment is important, since development of advanced HF, although rare in HCM, portends a poor prognosis. In RCM, HFpEF is common, while HFrEF occurs later and more frequently in amyloidosis or iron overload/haemochromatosis. Irrespective of RCM aetiology, HF is a harbinger of a poor outcome. Recent advances in our understanding of the mechanisms underlying the development of HF in cardiomyopathies have significant implications for therapeutic decision-making. In addition, new aetiology-specific treatment options (e.g. enzyme replacement therapy, transthyretin stabilizers, immunoadsorption, immunotherapy, etc.) have shown a potential to improve outcomes. Still, causative therapies of many cardiomyopathies are lacking, highlighting the need for the development of effective strategies to prevent and treat HF in cardiomyopathies.

Overview

Integrity signals

Registry

Crossref · 10.1002/ejhf.1461

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 229

  1. Pinto, 2016, Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 37, 1850, 10.1093/eurheartj/ehv727 · DOI
  2. Mozaffarian, 2016, Heart disease and stroke statistics-2016 update: a report from the American Heart Association, Circulation, 133, e38
  3. Codd, 1989, Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984, Circulation, 80, 564, 10.1161/01.CIR.80.3.564 · DOI
  4. Torp, 1978, Incidence of congestive cardiomyopathy, Postgrad Med J, 54, 435, 10.1136/pgmj.54.633.435 · DOI
  5. Miura, 2002, Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey, Heart, 87, 126, 10.1136/heart.87.2.126 · DOI
  6. Falase, 2012, Cardiomyopathies and myocardial disorders in Africa: present status and the way forward, Cardiovasc J Afr, 23, 552, 10.5830/CVJA-2012-046 · DOI
  7. Bozkurt, 2016, Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association, Circulation, 134, e579, 10.1161/CIR.0000000000000455 · DOI
  8. Kubanek, 2013, Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy, J Am Coll Cardiol, 61, 54, 10.1016/j.jacc.2012.07.072 · DOI
  9. Halliday, 2018, Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy, Eur J Heart Fail, 20, 1392, 10.1002/ejhf.1216 · DOI
  10. McNamara, 2011, Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study, J Am Coll Cardiol, 58, 1112, 10.1016/j.jacc.2011.05.033 · DOI
  11. Pecini, 2011, Heart failure etiology impacts survival of patients with heart failure, Int J Cardiol, 149, 211, 10.1016/j.ijcard.2010.01.011 · DOI
  12. Cohn, 2000, Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators, Eur J Heart Fail, 2, 439, 10.1016/S1388-9842(00)00130-6 · DOI
  13. 1999, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9 · DOI
  14. Adams, 2005, Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE), Am Heart J, 149, 209, 10.1016/j.ahj.2004.08.005 · DOI
  15. Thorvaldsen, 2016, Use of evidence-based therapy and survival in heart failure in Sweden 2003–2012, Eur J Heart Fail, 18, 503, 10.1002/ejhf.496 · DOI
  16. Shore, 2015, Characteristics, treatments, and outcomes of hospitalized heart failure patients stratified by etiologies of cardiomyopathy, JACC Heart Fail, 3, 906, 10.1016/j.jchf.2015.06.012 · DOI
  17. Rose, 2001, Long-term use of a left ventricular assist device for end-stage heart failure, N Engl J Med, 345, 1435, 10.1056/NEJMoa012175 · DOI
  18. Yoshioka, 2017, Outcome of heart transplantation after bridge-to-transplant strategy using various mechanical circulatory support devices, Interact Cardiovasc Thorac Surg, 25, 918, 10.1093/icvts/ivx201 · DOI
  19. Rossano, 2016, The registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Heart Transplantation Report-2016; focus theme: primary diagnostic indications for transplant, J Heart Lung Transplant, 35, 1185, 10.1016/j.healun.2016.08.018 · DOI
  20. Yusen, 2016, The registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; focus theme: primary diagnostic indications for transplant, J Heart Lung Transplant, 35, 1170, 10.1016/j.healun.2016.09.001 · DOI
  21. Lund, 2016, The registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; focus theme: primary diagnostic indications for transplant, J Heart Lung Transplant, 35, 1158, 10.1016/j.healun.2016.08.017 · DOI
  22. Richardson, 1996, Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies, Circulation, 93, 841, 10.1161/01.CIR.93.5.841 · DOI · Paper page
  23. Jefferies, 2010, Dilated cardiomyopathy, Lancet, 375, 752, 10.1016/S0140-6736(09)62023-7 · DOI
  24. Japp, 2016, The diagnosis and evaluation of dilated cardiomyopathy, J Am Coll Cardiol, 67, 2996, 10.1016/j.jacc.2016.03.590 · DOI
  25. Roberts, 2015, Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease, Sci Transl Med, 7, 270ra6, 10.1126/scitranslmed.3010134 · DOI
  26. van Rijsingen, 2014, Outcome in phospholamban R14del carriers: results of a large multicentre cohort study, Circ Cardiovasc Genet, 7, 455, 10.1161/CIRCGENETICS.113.000374 · DOI
  27. van der Zwaag, 2012, Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy, Eur J Heart Fail, 14, 1199, 10.1093/eurjhf/hfs119 · DOI
  28. Priori, 2015, 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), Eur Heart J, 36, 2793, 10.1093/eurheartj/ehv316 · DOI · Paper page
  29. Fayssoil, 2010, Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics, Heart Fail Rev, 15, 103, 10.1007/s10741-009-9156-8 · DOI
  30. Silva, 2017, Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy: a randomized clinical trial, JAMA Cardiol, 2, 190, 10.1001/jamacardio.2016.4801 · DOI
  31. Duboc, 2005, Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy, J Am Coll Cardiol, 45, 855, 10.1016/j.jacc.2004.09.078 · DOI
  32. Raman, 2015, Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial, Lancet Neurol, 14, 153, 10.1016/S1474-4422(14)70318-7 · DOI
  33. Caforio, 2013, Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 34, 2636, 10.1093/eurheartj/eht210 · DOI · Paper page
  34. Schulze, 1990, Antibodies to ADP-ATP carrier – an autoantigen in myocarditis and dilated cardiomyopathy – impair cardiac function, Circulation, 81, 959, 10.1161/01.CIR.81.3.959 · DOI
  35. Escher, 2014, Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome, Eur J Heart Fail, 16, 1066, 10.1002/ejhf.148 · DOI
  36. Nielsen, 2014, The presence of enterovirus, adenovirus, and parvovirus B19 in myocardial tissue samples from autopsies: an evaluation of their frequencies in deceased individuals with myocarditis and in non-inflamed control hearts, Forensic Sci Med Pathol, 10, 344, 10.1007/s12024-014-9570-7 · DOI
  37. Kitaura-Inenaga, 2003, Gene expression of cardiac mast cell chymase and tryptase in a murine model of heart failure caused by viral myocarditis, Circ J, 67, 881, 10.1253/circj.67.881 · DOI
  38. Mendez, 2001, The epidemiological features of heart failure in developing countries: a review of the literature, Int J Cardiol, 80, 213, 10.1016/S0167-5273(01)00497-1 · DOI
  39. Rossi, 1995, The challenge of chagasic cardiomyopathy. The pathologic roles of autonomic abnormalities, autoimmune mechanisms and microvascular changes, and therapeutic implications, Cardiology, 86, 1, 10.1159/000176822 · DOI
  40. Caforio, 2017, Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease, Eur Heart J, 38, 2649, 10.1093/eurheartj/ehx321 · DOI
  41. Caforio, 2007, Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives, Circulation, 115, 76, 10.1161/CIRCULATIONAHA.106.641472 · DOI
  42. Caforio, 1994, Evidence from family studies for autoimmunity in dilated cardiomyopathy, Lancet, 344, 773, 10.1016/S0140-6736(94)92339-6 · DOI
  43. Sliwa, 2010, Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy, Eur J Heart Fail, 12, 767, 10.1093/eurjhf/hfq120 · DOI
  44. Bauersachs, 2016, Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy, Eur J Heart Fail, 18, 1096, 10.1002/ejhf.586 · DOI
  45. Hilfiker-Kleiner, 2007, A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy, Cell, 128, 589, 10.1016/j.cell.2006.12.036 · DOI
  46. Forster, 2008, Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy, Eur J Heart Fail, 10, 861, 10.1016/j.ejheart.2008.07.005 · DOI
  47. Rizeq, 1994, Incidence of myocarditis in peripartum cardiomyopathy, Am J Cardiol, 74, 474, 10.1016/0002-9149(94)90906-7 · DOI
  48. Warraich, 2005, Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy, Am Heart J, 150, 263, 10.1016/j.ahj.2004.09.008 · DOI
  49. Patten, 2012, Cardiac angiogenic imbalance leads to peripartum cardiomyopathy, Nature, 485, 333, 10.1038/nature11040 · DOI
  50. Ware, 2016, Shared genetic predisposition in peripartum and dilated cardiomyopathies, N Engl J Med, 374, 233, 10.1056/NEJMoa1505517 · DOI
  51. Ewer, 2005, Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment, J Clin Oncol, 23, 7820, 10.1200/JCO.2005.13.300 · DOI
  52. Figueredo, 2011, Chemical cardiomyopathies: the negative effects of medications and nonprescribed drugs on the heart, Am J Med, 124, 480, 10.1016/j.amjmed.2010.11.031 · DOI
  53. Fauchier, 2000, Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy, Eur Heart J, 21, 306, 10.1053/euhj.1999.1761 · DOI
  54. Ameri, 2018, Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge, Eur J Heart Fail, 20, 879, 10.1002/ejhf.1165 · DOI
  55. Zamorano, 2016, 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), Eur Heart J, 37, 2768, 10.1093/eurheartj/ehw211 · DOI
  56. Pareek, 2018, Activity and outcomes of a cardio-oncology service in the United Kingdom – a five-year experience, Eur J Heart Fail, 20, 1721, 10.1002/ejhf.1292 · DOI
  57. Steinherz, 1991, Cardiac toxicity 4 to 20 years after completing anthracycline therapy, JAMA, 266, 1672, 10.1001/jama.1991.03470120074036 · DOI
  58. Wilcox, 2015, ‘Targeting the Heart’ in heart failure: myocardial recovery in heart failure with reduced ejection fraction, JACC Heart Fail, 3, 661, 10.1016/j.jchf.2015.04.011 · DOI
  59. Wittstein, 2005, Neurohumoral features of myocardial stunning due to sudden emotional stress, N Engl J Med, 352, 539, 10.1056/NEJMoa043046 · DOI
  60. Hilfiker-Kleiner, 2014, Pathophysiology and epidemiology of peripartum cardiomyopathy, Nat Rev Cardiol, 11, 364, 10.1038/nrcardio.2014.37 · DOI
  61. Fuster, 1981, The natural history of idiopathic dilated cardiomyopathy, Am J Cardiol, 47, 525, 10.1016/0002-9149(81)90534-8 · DOI
  62. Matsumura, 2006, Long-term prognosis of dilated cardiomyopathy revisited: an improvement in survival over the past 20 years, Circ J, 70, 376, 10.1253/circj.70.376 · DOI
  63. Halliday, 2019, Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial, Lancet, 10.1016/S0140-6736(18)32484-X · DOI
  64. Wilcox, 2012, Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF, Am Heart J, 163, 49, 10.1016/j.ahj.2011.10.001 · DOI
  65. Merlo, 2011, Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment, J Am Coll Cardiol, 57, 1468, 10.1016/j.jacc.2010.11.030 · DOI
  66. Martinez-Selles, 2012, Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis, Eur J Heart Fail, 14, 473, 10.1093/eurjhf/hfs026 · DOI
  67. Gulati, 2013, Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy, JAMA, 309, 896, 10.1001/jama.2013.1363 · DOI
  68. Rossi, 2011, Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy, Heart, 97, 1675, 10.1136/hrt.2011.225789 · DOI
  69. Nasser, 2017, Evolution of functional mitral regurgitation and prognosis in medically managed heart failure patients with reduced ejection fraction, JACC Heart Fail, 5, 652, 10.1016/j.jchf.2017.06.015 · DOI
  70. Waagstein, 1993, Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group, Lancet, 342, 1441, 10.1016/0140-6736(93)92930-R · DOI
  71. 1994, A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees, Circulation, 90, 1765, 10.1161/01.CIR.90.4.1765 · DOI
  72. Granger, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial, Lancet, 362, 772, 10.1016/S0140-6736(03)14284-5 · DOI · Paper page
  73. Swedberg, 2010, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study, Lancet, 376, 875, 10.1016/S0140-6736(10)61198-1 · DOI · Paper page
  74. Kadish, 2004, Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy, N Engl J Med, 350, 2151, 10.1056/NEJMoa033088 · DOI
  75. Singh, 1995, Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure, N Engl J Med, 333, 77, 10.1056/NEJM199507133330201 · DOI
  76. Elming Marie, 2017, Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure, Circulation, 136, 1772, 10.1161/CIRCULATIONAHA.117.028829 · DOI
  77. Bristow, 2016, Lessons learned and insights gained in the design, analysis, and outcomes of the COMPANION trial, JACC Heart Fail, 4, 521, 10.1016/j.jchf.2016.02.019 · DOI
  78. Zareba, 2011, Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT), Circulation, 123, 1061, 10.1161/CIRCULATIONAHA.110.960898 · DOI
  79. Cleland, 2005, The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med, 352, 1539, 10.1056/NEJMoa050496 · DOI
  80. De Bonis, 2012, Long-term results of mitral repair for functional mitral regurgitation in idiopathic dilated cardiomyopathy, Eur J Cardiothorac Surg, 42, 640, 10.1093/ejcts/ezs078 · DOI
  81. Feldman, 2011, Percutaneous repair or surgery for mitral regurgitation, N Engl J Med, 364, 1395, 10.1056/NEJMoa1009355 · DOI
  82. Obadia, 2018, Percutaneous repair or medical treatment for secondary mitral regurgitation, N Engl J Med, 379, 2297, 10.1056/NEJMoa1805374 · DOI
  83. Stone, 2018, Transcatheter mitral-valve repair in patients with heart failure, N Engl J Med, 379, 2307, 10.1056/NEJMoa1806640 · DOI · Paper page
  84. Frustaci, 2009, Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study, Eur Heart J, 30, 1995, 10.1093/eurheartj/ehp249 · DOI · Paper page
  85. Escher, 2016, Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy, Clin Res Cardiol, 105, 1011, 10.1007/s00392-016-1011-z · DOI
  86. Cooper, 2008, Usefulness of immunosuppression for giant cell myocarditis, Am J Cardiol, 102, 1535, 10.1016/j.amjcard.2008.07.041 · DOI
  87. Schultheiss, 2016, Betaferon in Chronic Viral Cardiomyopathy (BICC) trial: effects of interferon-beta treatment in patients with chronic viral cardiomyopathy, Clin Res Cardiol, 105, 763, 10.1007/s00392-016-0986-9 · DOI
  88. Felix, 2000, Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study, J Am Coll Cardiol, 35, 1590, 10.1016/S0735-1097(00)00568-4 · DOI
  89. Ohlow, 2017, Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: results from the observational prospective Bad Berka registry, J Cardiol, 69, 409, 10.1016/j.jjcc.2016.07.014 · DOI
  90. Weinmann, 2018, Add-on immunoadsorption shortly-after optimal medical treatment further significantly and persistently improves cardiac function and symptoms in recent-onset heart failure – a single center experience, Biomolecules, 8, E133, 10.3390/biom8040133 · DOI
  91. Farmakis, 2018, Anthracycline-induced cardiomyopathy: secrets and lies, Eur J Heart Fail, 20, 907, 10.1002/ejhf.1172 · DOI
  92. Hilfiker-Kleiner, 2017, Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study, Eur Heart J, 38, 2671, 10.1093/eurheartj/ehx355 · DOI
  93. Mirijello, 2017, Alcoholic cardiomyopathy: what is known and what is not known, Eur J Intern Med, 43, 1, 10.1016/j.ejim.2017.06.014 · DOI
  94. Johansen, 2017, Postnatal cardiac gene editing using CRISPR/Cas9 with AAV9-mediated delivery of short guide RNAs results in mosaic gene disruption, Circ Res, 121, 1168, 10.1161/CIRCRESAHA.116.310370 · DOI
  95. Elliott, 2014, 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
  96. Elliott, 2008, Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 29, 270, 10.1093/eurheartj/ehm342 · DOI
  97. Olivotto, 2009, The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice, J Cardiovasc Transl Res, 2, 349, 10.1007/s12265-009-9137-2 · DOI
  98. Maron, 2006, Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction, Circulation, 114, 2232, 10.1161/CIRCULATIONAHA.106.644682 · DOI
  99. Zou, 2004, Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults, Am J Med, 116, 14, 10.1016/j.amjmed.2003.05.009 · DOI
  100. Hada, 1987, Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening, Am J Cardiol, 59, 183, 10.1016/S0002-9149(87)80107-8 · DOI
  101. Corrado, 1998, Screening for hypertrophic cardiomyopathy in young athletes, N Engl J Med, 339, 364, 10.1056/NEJM199808063390602 · DOI
  102. Nistri, 2003, Screening for hypertrophic cardiomyopathy in a young male military population, Am J Cardiol, 91, 1021, 10.1016/S0002-9149(03)00132-2 · DOI
  103. Millat, 2010, Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy, Eur J Med Genet, 53, 261, 10.1016/j.ejmg.2010.07.007 · DOI · Paper page
  104. Maron, 2015, Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies, J Am Coll Cardiol, 65, 1915, 10.1016/j.jacc.2015.02.061 · DOI · Paper page
  105. Charron, 2018, The cardiomyopathy registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies, Eur Heart J, 39, 1784, 10.1093/eurheartj/ehx819 · DOI
  106. Maron, 2018, Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy, JACC Heart Fail, 6, 353, 10.1016/j.jchf.2017.09.011 · DOI
  107. Olivotto, 2001, Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy, Circulation, 104, 2517, 10.1161/hc4601.097997 · DOI · Paper page
  108. Kuperstein, 2018, De novo mitral regurgitation as a cause of heart failure exacerbation in patients with hypertrophic cardiomyopathy, Int J Cardiol, 252, 122, 10.1016/j.ijcard.2017.11.060 · DOI
  109. Melacini, 2010, Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy, Eur Heart J, 31, 2111, 10.1093/eurheartj/ehq136 · DOI
  110. Olivotto, 2012, Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging, Circ Heart Fail, 5, 535, 10.1161/CIRCHEARTFAILURE.112.967026 · DOI
  111. Thaman, 2005, Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy, Heart, 91, 920, 10.1136/hrt.2003.031161 · DOI
  112. Harris, 2006, Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy, Circulation, 114, 216, 10.1161/CIRCULATIONAHA.105.583500 · DOI
  113. Olivotto, 2008, Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy, Mayo Clin Proc, 83, 630, 10.1016/S0025-6196(11)60890-2 · DOI
  114. Mehta, 2004, Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey, Eur J Clin Invest, 34, 236, 10.1111/j.1365-2362.2004.01309.x · DOI
  115. Ferrantini, 2009, Mechanical and energetic consequences of HCM-causing mutations, J Cardiovasc Transl Res, 2, 441, 10.1007/s12265-009-9131-8 · DOI
  116. Tardiff, 2005, Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes, Heart Fail Rev, 10, 237, 10.1007/s10741-005-5253-5 · DOI
  117. Yacoub, 2007, ‘End-stage’ hypertrophic cardiomyopathy: from mystery to model, Nat Clin Pract Cardiovasc Med, 4, 232, 10.1038/ncpcardio0859 · DOI
  118. Maron, 2009, The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy, J Am Coll Cardiol, 54, 191, 10.1016/j.jacc.2008.11.069 · DOI
  119. Maron, 2009, The case for myocardial ischemia in hypertrophic cardiomyopathy, J Am Coll Cardiol, 54, 866, 10.1016/j.jacc.2009.04.072 · DOI
  120. Ho, 2009, Hypertrophic cardiomyopathy: preclinical and early phenotype, J Cardiovasc Transl Res, 2, 462, 10.1007/s12265-009-9124-7 · DOI
  121. Green, 2012, Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy, JACC Cardiovasc Imaging, 5, 370, 10.1016/j.jcmg.2011.11.021 · DOI
  122. Galati, 2016, Histological and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: a clinical-pathological study of 30 explanted hearts, Circ Heart Fail, 9, e003090, 10.1161/CIRCHEARTFAILURE.116.003090 · DOI
  123. Girolami, 2010, Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations, J Am Coll Cardiol, 55, 1444, 10.1016/j.jacc.2009.11.062 · DOI
  124. Garcia-Pavia, 2011, Genetic basis of end-stage hypertrophic cardiomyopathy, Eur J Heart Fail, 13, 1193, 10.1093/eurjhf/hfr110 · DOI
  125. Briguori, 1999, Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function, Am J Cardiol, 84, 309, 10.1016/S0002-9149(99)00282-9 · DOI
  126. Maron, 2008, Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy, Circulation, 118, 1541, 10.1161/CIRCULATIONAHA.108.781401 · DOI
  127. Nistri, 2006, Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy), Am J Cardiol, 98, 960, 10.1016/j.amjcard.2006.05.013 · DOI
  128. Sorajja, 2003, Myocardial bridging in adult patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 42, 889, 10.1016/S0735-1097(03)00854-4 · DOI
  129. Schafers, 1998, Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy, Circ Res, 82, 57, 10.1161/01.RES.82.1.57 · DOI
  130. Sherrid, 2016, The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context, J Am Coll Cardiol, 67, 1846, 10.1016/j.jacc.2016.01.071 · DOI
  131. Wu, 2010, Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity, Eur Heart J, 31, 1088, 10.1093/eurheartj/ehp588 · DOI
  132. Akhtar, 2018, Anderson-Fabry disease in heart failure, Biophys Rev, 10, 1107, 10.1007/s12551-018-0432-5 · DOI
  133. Weidemann, 2007, A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium, Eur Heart J, 28, 3020, 10.1093/eurheartj/ehm454 · DOI
  134. Calcagnino, 2011, Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease, J Am Coll Cardiol, 58, 88, 10.1016/j.jacc.2011.03.020 · DOI
  135. Torralba-Cabeza, 2011, Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease, Mol Genet Metab, 104, 301, 10.1016/j.ymgme.2011.06.021 · DOI
  136. Maron, 2009, Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy, JAMA, 301, 1253, 10.1001/jama.2009.371 · DOI
  137. Olivotto, 2010, Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy, Am J Cardiol, 106, 261, 10.1016/j.amjcard.2010.03.020 · DOI
  138. Maron, 2003, Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy, N Engl J Med, 348, 295, 10.1056/NEJMoa021332 · DOI · Paper page
  139. Maron, 2016, Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 67, 1399, 10.1016/j.jacc.2016.01.023 · DOI
  140. Efthimiadis, 2013, Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction, Circ J, 77, 2366, 10.1253/circj.CJ-12-1561 · DOI
  141. Biagini, 2009, Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy, Am J Cardiol, 104, 1727, 10.1016/j.amjcard.2009.07.057 · DOI
  142. Pasqualucci, 2015, Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy, Circ Heart Fail, 8, 1014, 10.1161/CIRCHEARTFAILURE.114.001843 · DOI · Paper page
  143. Rowin, 2014, Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant, Circ Heart Fail, 7, 967, 10.1161/CIRCHEARTFAILURE.114.001435 · DOI
  144. O'Hanlon, 2010, Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy, J Am Coll Cardiol, 56, 867, 10.1016/j.jacc.2010.05.010 · DOI
  145. Limongelli, 2017, Clinical and genetic characterization of patients with hypertrophic cardiomyopathy and right atrial enlargement, J Cardiovasc Med (Hagerstown), 18, 249, 10.2459/JCM.0000000000000361 · DOI
  146. Losi, 2010, . Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment, Cardiovasc Ultrasound, 8, 7, 10.1186/1476-7120-8-7 · DOI
  147. Linhart, 2007, Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey, Eur Heart J, 28, 1228, 10.1093/eurheartj/ehm153 · DOI
  148. Patel, 2015, Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry disease, Heart, 101, 961, 10.1136/heartjnl-2014-306782 · DOI
  149. Seydelmann, 2016, High-sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in Fabry disease, J Am Heart Assoc, 5, e002839, 10.1161/JAHA.115.002839 · DOI
  150. Rosmini, 2017, Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy, Heart, 103, 300, 10.1136/heartjnl-2016-310138 · DOI
  151. Shah, 2005, The natural history of left ventricular systolic function in Anderson-Fabry disease, Heart, 91, 533, 10.1136/hrt.2004.035584 · DOI
  152. Ommen, 2005, Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 46, 470, 10.1016/j.jacc.2005.02.090 · DOI
  153. Rastegar, 2017, Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience, Ann Cardiothorac Surg, 6, 353, 10.21037/acs.2017.07.07 · DOI
  154. Kuhn, 2008, Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience, Clin Res Cardiol, 97, 234, 10.1007/s00392-007-0616-7 · DOI
  155. Desai, 2013, Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction, Circulation, 128, 209, 10.1161/CIRCULATIONAHA.112.000849 · DOI · Paper page
  156. Faber, 2007, One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response, Clin Res Cardiol, 96, 864, 10.1007/s00392-007-0578-9 · DOI
  157. Qintar, 2012, Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy, Cochrane Database Syst Rev, CD008523
  158. Chan, 2014, Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy, Circulation, 130, 484, 10.1161/CIRCULATIONAHA.113.007094 · DOI · Paper page
  159. Rogers, 2008, Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy, Eur J Heart Fail, 10, 507, 10.1016/j.ejheart.2008.03.006 · DOI
  160. Topilsky, 2011, Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy, Circ Heart Fail, 4, 266, 10.1161/CIRCHEARTFAILURE.110.959288 · DOI
  161. Mehta, 2009, Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data, Lancet, 374, 1986, 10.1016/S0140-6736(09)61493-8 · DOI
  162. Banikazemi, 2007, Agalsidase-beta therapy for advanced Fabry disease: a randomized trial, Ann Intern Med, 146, 77, 10.7326/0003-4819-146-2-200701160-00148 · DOI
  163. El Dib, 2017, Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies, PLoS One, 12, e0173358, 10.1371/journal.pone.0173358 · DOI
  164. Hughes, 2017, Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study, J Med Genet, 54, 288, 10.1136/jmedgenet-2016-104178 · DOI
  165. Muntze, 2018, Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy, Eur Heart J, 39, 1861, 10.1093/eurheartj/ehy072 · DOI
  166. Prater, 2012, The emerging phenotype of long-term survivors with infantile Pompe disease, Genet Med, 14, 800, 10.1038/gim.2012.44 · DOI
  167. van Capelle, 2018, Cardiac outcome in classic infantile Pompe disease after 13years of treatment with recombinant human acid alpha-glucosidase, Int J Cardiol, 269, 104, 10.1016/j.ijcard.2018.07.091 · DOI
  168. D'Souza, 2014, Danon disease: clinical features, evaluation, and management, Circ Heart Fail, 7, 843, 10.1161/CIRCHEARTFAILURE.114.001105 · DOI
  169. Geske, 2016, Differentiation of constriction and restriction: complex cardiovascular hemodynamics, J Am Coll Cardiol, 68, 2329, 10.1016/j.jacc.2016.08.050 · DOI
  170. Kushwaha, 1997, Restrictive cardiomyopathy, N Engl J Med, 336, 267, 10.1056/NEJM199701233360407 · DOI
  171. Pereira, 2018, Spectrum of restrictive and infiltrative cardiomyopathies: Part 1 of a 2-Part Series, J Am Coll Cardiol, 71, 1130, 10.1016/j.jacc.2018.01.016 · DOI
  172. Murphy, 2010, Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment, J Card Fail, 16, 888, 10.1016/j.cardfail.2010.05.009 · DOI
  173. Muchtar, 2017, Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy, Circ Res, 121, 819, 10.1161/CIRCRESAHA.117.310982 · DOI
  174. Ammash, 2000, Clinical profile and outcome of idiopathic restrictive cardiomyopathy, Circulation, 101, 2490, 10.1161/01.CIR.101.21.2490 · DOI
  175. Kubo, 2007, Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype, J Am Coll Cardiol, 49, 2419, 10.1016/j.jacc.2007.02.061 · DOI
  176. Rich, 1997, Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults, J Am Geriatr Soc, 45, 968, 10.1111/j.1532-5415.1997.tb02968.x · DOI
  177. Waller, 1983, Cardiovascular disease in the very elderly. Analysis of 40 necropsy patients aged 90 years or over, Am J Cardiol, 51, 403, 10.1016/S0002-9149(83)80072-1 · DOI
  178. Castano, 2017, Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, Eur Heart J, 38, 2879, 10.1093/eurheartj/ehx350 · DOI
  179. Gonzalez-Lopez, 2015, Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction, Eur Heart J, 36, 2585, 10.1093/eurheartj/ehv338 · DOI
  180. Mogensen, 2009, Restrictive cardiomyopathy, Curr Opin Cardiol, 24, 214, 10.1097/HCO.0b013e32832a1d2e · DOI
  181. Maurer, 2017, Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis, Circulation, 135, 1357, 10.1161/CIRCULATIONAHA.116.024438 · DOI
  182. Rubin, 2018, Myocardial contraction fraction by M-mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis, J Card Fail, 24, 504, 10.1016/j.cardfail.2018.07.001 · DOI
  183. Clemmensen, 2017, Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis, Eur J Heart Fail, 19, 1457, 10.1002/ejhf.899 · DOI
  184. Rivenes, 2000, Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy, Circulation, 102, 876, 10.1161/01.CIR.102.8.876 · DOI
  185. Rammos, 2017, Restrictive cardiomyopathies: the importance of noninvasive cardiac imaging modalities in diagnosis and treatment – a systematic review, Radiol Res Pract, 2017, 2874902
  186. Brenner, 2004, Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress, Circ Res, 94, 1008, 10.1161/01.RES.0000126569.75419.74 · DOI
  187. Falk, 2016, AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy, J Am Coll Cardiol, 68, 1323, 10.1016/j.jacc.2016.06.053 · DOI
  188. Skinner, 1996, Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only, Am J Med, 100, 290, 10.1016/S0002-9343(97)89487-9 · DOI
  189. Kyle, 1995, Primary systemic amyloidosis: clinical and laboratory features in 474 cases, Semin Hematol, 32, 45
  190. Kumar, 2012, Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements, J Clin Oncol, 30, 989, 10.1200/JCO.2011.38.5724 · DOI
  191. Banypersad, 2015, T1 mapping and survival in systemic light-chain amyloidosis, Eur Heart J, 36, 244, 10.1093/eurheartj/ehu444 · DOI
  192. Castano, 2015, Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs, Heart Fail Rev, 20, 163, 10.1007/s10741-014-9462-7 · DOI
  193. Gertz, 2015, Diagnosis, prognosis, and therapy of transthyretin amyloidosis, J Am Coll Cardiol, 66, 2451, 10.1016/j.jacc.2015.09.075 · DOI · Paper page
  194. Birnie, 2016, Cardiac sarcoidosis, J Am Coll Cardiol, 68, 411, 10.1016/j.jacc.2016.03.605 · DOI · Paper page
  195. Silverman, 1978, Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis, Circulation, 58, 1204, 10.1161/01.CIR.58.6.1204 · DOI
  196. Martusewicz-Boros, 2016, Cardiac sarcoidosis: is it more common in men?, Lung, 194, 61, 10.1007/s00408-015-9805-8 · DOI
  197. Kandolin, 2015, Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study, Circulation, 131, 624, 10.1161/CIRCULATIONAHA.114.011522 · DOI
  198. Segura, 2014, Granulomatous myocarditis in severe heart failure patients undergoing implantation of a left ventricular assist device, Cardiovasc Pathol, 23, 17, 10.1016/j.carpath.2013.06.005 · DOI
  199. Roberts, 2014, Morphologic features of cardiac sarcoidosis in native hearts of patients having cardiac transplantation, Am J Cardiol, 113, 706, 10.1016/j.amjcard.2013.11.015 · DOI
  200. Kandolin, 2011, Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults, Circ Arrhythm Electrophysiol, 4, 303, 10.1161/CIRCEP.110.959254 · DOI

200 of 229 shown

Cited by

Sorted by citations

See all 346

Metadata

Authors
Seferović, P. M., Polovina, M., Bauersachs, J., Arad, M., Ben Gal, T., Lund, L. H., Felix, S. B., Arbustini, E., Caforio, A. L. P., Farmakis, D., Filippatos, G. S., Gialafos, E., Kanjuh, V., Krljanac, G., Limongelli, G., Linhart, A., Lyon, A. R., Maksimović, R., Miličić, D., Milinković, I., Noutsias, M., Oto, A., Oto, Ö., Pavlović, S. U., Piepoli, M. F., Ristić, A. D., Rosano, G. M. C., Seggewiss, H., Ašanin, M., Seferović, J. P., Ruschitzka, F., Čelutkiene, J., Jaarsma, T., Mueller, C., Moura, B., Hill, L., Volterrani, M., Lopatin, Y., Metra, M., Backs, J., Mullens, W., Chioncel, O., de Boer, R. A., Anker, S., Rapezzi, C., Coats, A. J. S., & Tschöpe, C.
Venue
European Journal of Heart Failure
Publisher
Oxford University Press (OUP)
Published
2019-04-16
Volume
21
Issue
5
Pages
553-576
ISSN
  • 1388-9842
  • 1879-0844
DOI
10.1002/ejhf.1461
Cited by
346
References
16
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review